viracept
roche registration ltd. - nelfinavir - hiv-infeksjoner - antivirale midler til systemisk bruk - viracept er indisert ved antiretroviral kombinationsbehandling av hiv-1-infiserte voksne, ungdom og barn på tre år og eldre. i protease-inhibitor (pi)-erfarne pasienter, valg av nelfinavir bør være basert på individuelle viral motstand testing og behandling historie.
xtandi
astellas pharma europe b.v. - enzalutamide - prostata neoplasmer - endokrin terapi - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
alzane 5 mg/ ml
laboratorios syva s.a. (2) - atipamezolhydroklorid - injeksjonsvæske, oppløsning - 5 mg/ ml
alfaxan 10 mg/ ml
jurox (ireland) limited - alfaksalon - injeksjonsvæske, oppløsning - 10 mg/ ml
diclofenac bluefish 50 mg
bluefish pharmaceuticals ab - diklofenaknatrium - enterotablett - 50 mg
diclofenac bluefish 25 mg
bluefish pharmaceuticals ab - diklofenaknatrium - enterotablett - 25 mg
dicuno 50 mg
vitabalans oy - diklofenakkalium - tablett, filmdrasjert - 50 mg
dicuno 25 mg
vitabalans oy - diklofenakkalium - tablett, filmdrasjert - 25 mg
ebastin orifarm 10 mg
orifarm generics a/s - ebastin - tablett, filmdrasjert - 10 mg
ebastin orifarm 20 mg
orifarm generics a/s - ebastin - tablett, filmdrasjert - 20 mg